Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2014-2015

ABSTRACT

The purpose of this study is to determine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine as first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma. Detailed Description Advanced pancreatic ductal adenocarcinoma is a fatal disease with about 6 months of median overall survival (OS). Gemcitabine is the only approved single agent. Gemcitabine-based chemotherapy did not show benefit in OS during the past decade. The recent phase III trial MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an improvement in overall response rate (ORR), progression free survival (PFS) and OS, with nab-paclitaxel (125 mg/m2 on day 1, 8 and 15 every 28 days) plus gemcitabine (1000 mg/m2 on day 1, 8 and 15 every 28 days) compared to gemcitabine alone. Accordingly the combination of nab-paclitaxel with gemcitabine became one of standard treatments in metastatic pancreatic cancer. A Chinese phase II trial showed the modified dosage of nab-paclitaxel (120 mg/m2 on day 1 and 8 every 21 days) plus gemcitabine (1000 mg/m2 on day 1 and 8 every 21 days) is more suitable for Chinese patients. This study aims to explore the efficacy and safety of the tentative dosage of nab-paclitaxel (125 mg/m2 on day 1 and 8, every 21 days) and gemcitabine (1000 mg/m2 on day 1 and 8, every 21 days) for Chinese patients. More... »

URL

https://clinicaltrials.gov/show/NCT02135822

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine as first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma.\n\nDetailed Description\nAdvanced pancreatic ductal adenocarcinoma is a fatal disease with about 6 months of median overall survival (OS). Gemcitabine is the only approved single agent. Gemcitabine-based chemotherapy did not show benefit in OS during the past decade. The recent phase III trial MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an improvement in overall response rate (ORR), progression free survival (PFS) and OS, with nab-paclitaxel (125 mg/m2 on day 1, 8 and 15 every 28 days) plus gemcitabine (1000 mg/m2 on day 1, 8 and 15 every 28 days) compared to gemcitabine alone. Accordingly the combination of nab-paclitaxel with gemcitabine became one of standard treatments in metastatic pancreatic cancer. A Chinese phase II trial showed the modified dosage of nab-paclitaxel (120 mg/m2 on day 1 and 8 every 21 days) plus gemcitabine (1000 mg/m2 on day 1 and 8 every 21 days) is more suitable for Chinese patients. This study aims to explore the efficacy and safety of the tentative dosage of nab-paclitaxel (125 mg/m2 on day 1 and 8, every 21 days) and gemcitabine (1000 mg/m2 on day 1 and 8, every 21 days) for Chinese patients.", 
    "endDate": "2015-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02135822", 
    "keywords": [
      "phase II trial", 
      "gemcitabine", 
      "first-line treatment", 
      "patient", 
      "Pancreatic Neoplasm", 
      "efficacy", 
      "safety", 
      "nanoparticles", 
      "Paclitaxel", 
      "pancreatic ductal adenocarcinoma", 
      "fatal disease", 
      "overall survival", 
      "single agent", 
      "benefit", 
      "past decade", 
      "Phase III trial", 
      "pancreatic adenocarcinoma", 
      "improvement", 
      "overall response rate", 
      "Disease-Free Survival", 
      "standard treatment", 
      "metastatic pancreatic cancer", 
      "dosage"
    ], 
    "name": "Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02135822"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00016.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.414252.4", 
        "type": "Organization"
      }
    ], 
    "startDate": "2014-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12885-017-3887-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099924627", 
          "https://doi.org/10.1186/s12885-017-3887-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-017-3887-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099924627", 
          "https://doi.org/10.1186/s12885-017-3887-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02135822"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02135822'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02135822'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02135822'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02135822'


 

This table displays all metadata directly associated to this object as RDF triples.

46 TRIPLES      16 PREDICATES      39 URIs      32 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02135822 schema:about anzsrc-for:3142
2 schema:description The purpose of this study is to determine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine as first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma. Detailed Description Advanced pancreatic ductal adenocarcinoma is a fatal disease with about 6 months of median overall survival (OS). Gemcitabine is the only approved single agent. Gemcitabine-based chemotherapy did not show benefit in OS during the past decade. The recent phase III trial MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an improvement in overall response rate (ORR), progression free survival (PFS) and OS, with nab-paclitaxel (125 mg/m2 on day 1, 8 and 15 every 28 days) plus gemcitabine (1000 mg/m2 on day 1, 8 and 15 every 28 days) compared to gemcitabine alone. Accordingly the combination of nab-paclitaxel with gemcitabine became one of standard treatments in metastatic pancreatic cancer. A Chinese phase II trial showed the modified dosage of nab-paclitaxel (120 mg/m2 on day 1 and 8 every 21 days) plus gemcitabine (1000 mg/m2 on day 1 and 8 every 21 days) is more suitable for Chinese patients. This study aims to explore the efficacy and safety of the tentative dosage of nab-paclitaxel (125 mg/m2 on day 1 and 8, every 21 days) and gemcitabine (1000 mg/m2 on day 1 and 8, every 21 days) for Chinese patients.
3 schema:endDate 2015-12-01T00:00:00Z
4 schema:keywords Disease-Free Survival
5 Paclitaxel
6 Pancreatic Neoplasm
7 Phase III trial
8 benefit
9 dosage
10 efficacy
11 fatal disease
12 first-line treatment
13 gemcitabine
14 improvement
15 metastatic pancreatic cancer
16 nanoparticles
17 overall response rate
18 overall survival
19 pancreatic adenocarcinoma
20 pancreatic ductal adenocarcinoma
21 past decade
22 patient
23 phase II trial
24 safety
25 single agent
26 standard treatment
27 schema:name Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer
28 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02135822
29 schema:sdDatePublished 2019-03-07T15:25
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher N4622602bc35247f89adc533e3032296a
32 schema:sponsor https://www.grid.ac/institutes/grid.414252.4
33 schema:startDate 2014-05-01T00:00:00Z
34 schema:subjectOf sg:pub.10.1186/s12885-017-3887-z
35 schema:url https://clinicaltrials.gov/show/NCT02135822
36 sgo:license sg:explorer/license/
37 sgo:sdDataset clinical_trials
38 rdf:type schema:MedicalStudy
39 N4622602bc35247f89adc533e3032296a schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
42 rdf:type schema:DefinedTerm
43 sg:pub.10.1186/s12885-017-3887-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1099924627
44 https://doi.org/10.1186/s12885-017-3887-z
45 rdf:type schema:CreativeWork
46 https://www.grid.ac/institutes/grid.414252.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...